TARA Should I Buy

Oppenheimer raised the firm's price target on Protara Therapeutics to $28 from $25 and keeps an Outperform rating on the shares. TARA-002's opportunity in lymphatic malformations looks increasingly compelling after Tuesday's event that featured incremental data and regulatory clarity, the firm says. The combination of high early response rates, clean tolerability, emerging durability, limited dosing burden, and key opinion leader enthusiasm strengthen the case that TARA-002 could become a preferred therapy for macrocystic and macro-dominant mixed LMs-lesion types that demand attention yet which lack approved treatments and for which current surgical/off-label options are suboptimal on both efficacy/durability and complications/safety. Oppenheimer sees about $250M peak U.S. sales potential through ultra-orphan pricing, a concentrated specialist base, and minimal practice burden.